Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 1.00 |
| ▸ | CNR2 | P34972 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | TSPO | P30536 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975030 | 0.91 | CNR1 (0.84) | CNR1CNR2HTR1ATSPOOPRM1 | |
| SCHEMBL3819916 | 0.88 | CNR1 (0.79) | CNR1CNR2HTR1ATSPOOPRM1 | |
| Jhu-75528 SCHEMBL31038583 | 0.84 | CNR1 (1.00) | CNR1CNR2HTR1ATSPOOPRM1 | |
| SCHEMBL7977816 | 0.79 | CNR1 (0.65) | CNR1CNR2HTR1ATSPOOPRM1 | |
| SCHEMBL3825752 | 0.75 | CNR1 (1.00) | CNR1CNR2OPRM1OPRK1 | |
| SCHEMBL10170758 | 0.75 | CNR1 (1.00) | CNR1CNR2OPRM1OPRK1 | |
| SCHEMBL4612148 | 0.75 | CNR1 (0.80) | CNR1CNR2HTR1ATSPOOPRM1 | |
| SCHEMBL3819909 | 0.74 | CNR1 (0.61) | CNR1CNR2HTR1ATSPOOPRM1 | |
| SCHEMBL4612839 | 0.73 | CNR1 (0.91) | CNR1CNR2OPRM1OPRK1 | |
| SCHEMBL3825455 | 0.73 | CNR1 (0.59) | CNR1CNR2HTR1ATSPOOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009140210-A2 | RADIOTRACERS FOR IMAGING CANNABINOID SUB-TYPE1 (CB1) RECEPTOR | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-11-19 | — | — | WO | disclosed |